Tocilizumab in Refractory ASS-ILD

Clinical trial NCT07662265 · COMPLETED

Trial details

NCT number: NCT07662265
Sponsor: Hu Yinan
Status: COMPLETED
Study type: OBSERVATIONAL

Antisynthetase Syndrome Tocilizumab

Start date: 2022-01-01
Primary completion: 2025-10-31
Enrollment: 111

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.